









Markets
/
Stocks
/
nasdaq-mynz
/

Mainz Biomed NV

MYNZ



View Detailed Chart

1.170USD

+0.020+1.74%

Close 12/24, 13:00（ET）Quotes delayed by 15 min

4.79MMarket Cap

LossP/E TTM



Mainz Biomed NV

1.170

+0.020+1.74%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

+1.74%

5 Days

+9.35%

1 Month

+21.68%

6 Months

-18.18%

Year to Date

-72.92%

1 Year

-75.73%

View Detailed Chart

TradingKey Stock Score of Mainz Biomed NV

Currency: USD Updated: 2025-12-24

Key Insights

Mainz Biomed NV's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered undervalued, ranking 68/78 in the Healthcare Providers & Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 14.00.In the medium term, the stock price is expected to trend down.The company has shown average stock market performance over the past month, with weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Mainz Biomed NV's Score

Industry at a Glance

Industry Ranking

68 / 78

Overall Ranking

375 / 4562

Industry

Healthcare Providers & Services

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Buy

Current Rating

14.000

Target Price

+1196.30%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Mainz Biomed NV Highlights

StrengthsRisks

Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 68.72% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 893.99K.

Overvalued

The company’s latest PE is -0.05, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 386.03K shares, increasing 27.24% quarter-over-quarter.